I3 Nirf
1 known investors
i3 develops intravascular imaging technology that combines ultrasound (IVUS) with near-infrared fluorescence (NIRF) for physicians performing percutaneous coronary intervention procedures. The technology provides real-time visualization of vascular anatomy and tissue characteristics to improve guidewire placement and stent positioning during coronary angioplasty.
Investors · 1
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does I3 Nirf do?
- i3 develops intravascular imaging technology that combines ultrasound (IVUS) with near-infrared fluorescence (NIRF) for physicians performing percutaneous coronary intervention procedures. The technology provides real-time visualization of vascular anatomy and tissue characteristics to improve guidewire placement and stent positioning during coronary angioplasty.
- Who are I3 Nirf's investors?
- I3 Nirf's investors include Broadview Ventures.